Osteonecrosis of the jaw (ONJ) among intravenous (IV) bisphosphonate- and/or bevacizumab-treated patients (pts) at Memorial Sloan-Kettering Cancer Center (MSKCC)

Authors :: Cherry L. Estilo
Heather L. McArthur
Maura N. Dickler
Clifford A. Hudis
Jane Howard
Monica Fornier
Joseph M. Huryn
T. Williams
TA Traina
Source :: Journal of Clinical Oncology. 26:9588-9588
Publication Year :: 2008
Publisher :: American Society of Clinical Oncology (ASCO), 2008.
Abstract: 9588 Background: ONJ is diagnosed with increasing frequency among IV bisphosponate (IVBP)-treated cancer pts, in the range of 1–10 per 100 treated pts depending on duration of therapy (Khosla 2007)...

Subjects :: Cancer Research
medicine.medical_specialty
Bevacizumab
business.industry
medicine.medical_treatment
Cancer
macromolecular substances
Bisphosphonate
medicine.disease
Surgery
carbohydrates (lipids)
stomatognathic diseases
Oncology
otorhinolaryngologic diseases
medicine
bacteria
business
Osteonecrosis of the jaw
medicine.drug

Full Text Access

Tools